炎症治疗在动脉粥样硬化中的研究进展

Treatment of Inflammation in Atherosclerosis

动脉粥样硬化(AS)是心脑血管疾病的主要病理基础,它通常被认为是由脂代谢失衡引起的一种慢性疾病。近年来,血管壁炎症的激活及调控机制的失衡已被证实在AS的发生和进展中起到关键作用。到目前为止,大多数药物治疗的目的是控制血脂等传统危险因素,但AS继发的临床事件仍不断发生,这在很大程度上反映了目前治疗方法无法充分控制残余的炎症反应。因此,以炎症作为延缓AS进展的治疗靶点得到越来越多的认可。

Atherosclerosis(AS)is the main pathological basis of cardiovascular diseases,and it is usually considered as a chronic disease caused by imbalance of lipid metabolism.In recent years,the activation of inflammation in the vascular wall and the imbalance of regulatory mechanisms have been shown to play a key role in the development and progression of AS.To date,most pharmacological treatments have been aimed at controlling traditional risk factors such as lipids,but clinical events secondary to AS continue to occur,largely reflecting the inability of contemporary therapies to adequately control residual inflammatory responses.Therefore,the use of inflammation as a therapeutic target to slow the progression of AS is gaining increasing recognition.